Mission Statement, Vision, & Core Values (2026) of Sansure Biotech Inc.

Founded in 2008, Sansure Biotech Inc. (688289.SS) has rapidly scaled from a Changsha-based innovator into a global leader in precision diagnostics, boasting more than 1,000 products and over 2,200 high-quality testing services that surpass domestic and international standards, deployed across upwards of 10,000 benchmark hospitals and laboratories in more than 160 countries and regions; with over 40% of its workforce focused on R&D, 1,400+ patents worldwide, subsidiaries spanning the UK, France, US and multiple Asian markets, and a 2020 listing on the Shanghai STAR Market, Sansure's mission of 'Innovating Life Tech For All,' vision of 'Building a healthier future as a world-class leader in life science innovation,' and its IShare core values (Innovation, Intelligence, Service, Health, Happiness, Accessible, Reliable, Accurate, Respectable, Ecosystem) drive a data-backed push to make precision diagnostics more accessible, reliable and integrated into everyday health management for billions of people globally

Sansure Biotech Inc. (688289.SS) - Intro

• Deliver accessible, reliable, and innovative molecular diagnostic solutions that improve clinical outcomes and public health worldwide.
• Advance gene technology to enable earlier, more accurate diagnosis and personalized care.
• Support health systems and communities through high-quality testing services and scalable diagnostic platforms.

• Be a global leader in molecular diagnostics, recognized for scientific excellence, widespread clinical adoption, and measurable contributions to disease prevention and management.
• Create a future where rapid, precise diagnostics empower clinicians and patients across all regions and healthcare settings.

• Innovation: Sustained investment in R&D-over 40% of employees dedicated to research and development-drives continuous product and platform advancement.
• Quality: Development of more than 1,000 products and 2,200+ testing services that meet or exceed domestic and global standards.
• Global Responsibility: Commitment to serving billions of people across 160+ countries and regions through scalable solutions and partnerships.
• Integrity: Compliance with regulatory frameworks, transparency in clinical performance, and protection of patient data.
• Collaboration: Working with benchmark hospitals, laboratories, and public health agencies-over 10,000 institutional users globally-to translate innovation into impact.

• R&D-First Product Roadmap: Prioritize gene-based assays and platform integration to expand the 1,000+ product portfolio with clinically differentiated offerings.
• Global Market Penetration: Strengthen local regulatory approvals, supply chains, and clinical partnerships to deepen adoption across the 160+ countries currently served.
• Service-Platform Integration: Scale independent clinical laboratory services and instrument-reagent ecosystems to increase utilization among 10,000+ institutional partners.
• Intellectual Property & Quality Assurance: Leverage 1,400+ patents and robust quality systems to protect innovations and ensure consistent performance across markets.

Sansure Biotech Inc. (688289.SS) - Overview

• "Innovating Life Tech For All" - develop high-quality, full-scenario diagnostic solutions supported by big data to make precision diagnostics reliable and accessible across clinical, community and at‑home settings.
• Commitment to healthcare equity: transform proactive health management into a routine, accessible, and inevitable part of life for diverse populations worldwide.
• Integrate advanced molecular diagnostics, digital platforms and data analytics to extend healthy lifespan and enable earlier, actionable interventions.

• Become the benchmark global provider of integrated precision diagnostics and life-tech ecosystems that empower clinicians, public health systems and individuals.
• Scale solutions from tertiary hospitals to grassroots clinics and consumer health, reducing diagnostic gaps between regions and populations.
• Leverage proprietary assays, instrument platforms and cloud-based big-data intelligence to anticipate disease trends and optimize care pathways.

• Innovation - sustained, high-intensity R&D to advance assay sensitivity, throughput and portability.
• Accessibility - cost-effective, scalable deployment across varied healthcare tiers and geographies.
• Quality & Compliance - strict quality management and regulatory alignment across markets.
• Data-Driven Impact - use of big data and real-world evidence to refine products and public-health responses.
• Collaboration - partnerships with hospitals, public-health agencies and industry to broaden reach and efficacy.

• Full‑scenario product lines - bench, POCT, near‑patient and at‑home diagnostics integrated with cloud analytics.
• Big data and platform development - centralized data lakes and AI models to improve assay interpretation, epidemiological insights and product iteration.
• Market expansion - targeted rollout into emerging markets and strengthening grassroots healthcare penetration through lower‑cost, high‑throughput solutions.
• Partnerships & collaborations - clinical trials, public-health projects and OEM/co‑development agreements to accelerate adoption and validation.

• Business model unites durable instrument sales with recurring consumables and reagent revenue for predictable cash flow.
• Continuous R&D reinvestment supports product differentiation and maintains regulatory approvals across jurisdictions.
• Public-health relevance and global deployments enhance resilience to cyclical demand shifts.

Sansure Biotech Inc. (688289.SS) - Mission Statement

• Mission: Develop reliable, affordable precision diagnostics and life‑science tools that enable earlier, more accurate disease detection and guide clinical decision‑making.
• Strategic focus areas: molecular diagnostics (PCR & isothermal platforms), nucleic acid extraction, and point‑of‑care testing.
• Operational levers: accelerated product registration, expanded global distribution, and partnerships with research institutions and hospitals.

• Global leadership: strive for world‑class competitiveness and international impact across diagnostics markets.
• Innovation‑driven growth: prioritize breakthrough R&D to set new standards in precision diagnostics.
• Quality and reliability: maintain stringent quality systems and regulatory compliance to ensure clinical trust.
• Health impact: expand access to diagnostics to improve population‑level health outcomes.

• R&D orientation: increasing share of revenue allocated to R&D to sustain technological leadership.
• Global expansion: registration and distribution networks across multiple regions to support export growth.
• Manufacturing scale: capacity investments to support rapid deployment during public‑health surges.

• Scientific excellence - rigorous validation and continual innovation in assay and platform development.
• Clinical responsibility - prioritize patient safety, accuracy and clinical utility.
• Global stewardship - broaden access to diagnostics in underserved markets.
• Integrity and compliance - adhere to international quality and regulatory standards.
• Collaboration - partner with academic, clinical and industry stakeholders to accelerate translational impact.

• Expand product pipeline: prioritize next‑generation molecular assays and integrated sample‑to‑answer systems.
• Scale manufacturing: increase automated capacity to shorten lead times and respond to epidemics.
• Regulatory strategy: pursue CE, FDA and regional authorizations to widen addressable markets.
• Market development: strengthen distributor networks and clinical evidence generation in target geographies.

Sansure Biotech Inc. (688289.SS) - Vision Statement

• Drive continuous innovation in molecular diagnostics and in vitro testing platforms to expand early detection, precision treatment guidance, and public‑health surveillance capabilities.
• Scale global accessibility so high‑quality diagnostic tools reach hospitals, community clinics, and low‑resource settings across continents.
• Build an ecosystem of partners-clinicians, academic researchers, industry players, and public health agencies-to co‑create solutions that improve population health and commercial sustainability.

• Innovation (I): relentless investment in R&D to create next‑generation diagnostic technologies, assay chemistries, and integrated testing systems.
• Intelligence: leveraging data, AI, and digital diagnostics to improve test interpretation and clinical decision support.
• Service (S): customer‑centric after‑sales support, clinical validation services, and training to ensure proper test deployment and use.
• Health & Happiness: prioritizing patient outcomes, customer satisfaction, and employee well‑being in strategic decisions.
• Accessible & Reliable: ensuring affordability, regulatory compliance, and operational robustness so diagnostics perform reliably worldwide.
• Accurate: rigorous quality systems and external validations to guarantee test sensitivity and specificity meet clinical needs.
• Respectable: ethical conduct, regulatory transparency, and adherence to international standards.
• Ecosystem: co‑creation with partners to drive shared value, joint advancement, and sustainable industry growth.

• Innovation: sustained capital allocation to R&D, incubator programs, and strategic acquisitions for platform technologies.
• Service: expanded field service teams, digital support portals, and local training centers in target regions.
• Accessible & Reliable: tiered product portfolios (high‑throughput, point‑of‑care, and near‑patient) to serve tertiary hospitals to rural clinics.
• Ecosystem: formal collaboration agreements with universities, hospitals, and global NGOs to co‑develop assays and deploy diagnostics in public‑health campaigns.

• Capital allocation balances growth and profitability: maintain healthy operating cash flow to fund R&D and international expansion.
• Market dynamics: rising demand for infectious disease surveillance, oncology companion diagnostics, and decentralized testing supports long‑term growth.
• Investor focus: consistent R&D intensity and visible pathway to margin expansion are key drivers of investor confidence.